PPCB (Propanc Biopharma) FCF Margin % : 0.00% (As of Sep. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Propanc Biopharma FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Propanc Biopharma's Free Cash Flow for the three months ended in Sep. 2024 was $-0.24 Mil. Propanc Biopharma's Revenue for the three months ended in Sep. 2024 was $0.00 Mil. Therefore, Propanc Biopharma's FCF Margin % for the quarter that ended in Sep. 2024 was 0.00%.

As of today, Propanc Biopharma's current FCF Yield % is -530.38%.

The historical rank and industry rank for Propanc Biopharma's FCF Margin % or its related term are showing as below:

PPCB's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -145.32
* Ranked among companies with meaningful FCF Margin % only.

Propanc Biopharma FCF Margin % Historical Data

The historical data trend for Propanc Biopharma's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Propanc Biopharma FCF Margin % Chart

Propanc Biopharma Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

FCF Margin %

Get a 7-Day Free Trial

Propanc Biopharma Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Propanc Biopharma's FCF Margin %

For the Biotechnology subindustry, Propanc Biopharma's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Propanc Biopharma's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Propanc Biopharma's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Propanc Biopharma's FCF Margin % falls into.

Propanc Biopharma FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Propanc Biopharma's FCF Margin for the fiscal year that ended in Jun. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Jun. 2024 )	/	Revenue (A: Jun. 2024 )
	=	-0.935	/	0
	=	%

Propanc Biopharma's FCF Margin for the quarter that ended in Sep. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	-0.236	/	0
	=	%

Propanc Biopharma FCF Margin % Related Terms

Thank you for viewing the detailed overview of Propanc Biopharma's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Propanc Biopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Propanc Biopharma Inc (OTCPK:PPCB) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

302, 6 Butler Street, Cambwerwell, VIC, AUS, 3124

Website

https://www.propanc.com

Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.

Executives

Josef Zelinger	director	59 SEYMOUR ROAD, ELSTERNWICK C3 3185
Carlo M Campiciano	officer: CFO & Secretary	C/O. PROPANC BIOPHARMA,INC., 302, 6 BUTLER STREET, CAMBERWELL C3 3124
Julian Norman Kenyon	director	BEECHWOOD, EMBLEY LANE, EAST WELLOW, ROMSEY HAMPSHIRE X0 SO516DN
James Andrew Nathanielsz	director, officer: CEO, CFO, Secretary, Treasurer	1/76 SUMMERHILL ROAD, GLEN IRIS, VICTORIA C3 3146